{"mainPropery":{"diseaseId":6557,"diseaseName":"Hemangioendothelioma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/6557/hemangioendothelioma","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"UMLS","identifierId":"C0018915"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":424,"resourceName":"Sarcoma Alliance","abbreviation":"","address1":"775 E. Blithedale #334","address2":"","address3":"","address4":"","address5":"","city":"Mill Valley","state":"CA","zip":"94941","country":"United States","phone":"+1-415-381-7236","tty":"","tollFree":"+1-415-381-7235","fax":"","email":"info@sarcomaalliance.org","url":"https://sarcomaalliance.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed/?term=hemangioendothelioma+%5Bti%5D+review' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Hemangioendothelioma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Hemangioendothelioma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Hemangioendothelioma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":583,"resourceId":120,"resourceName":"American Cancer Society","descriptionText":"The <a href='http://www.cancer.org/Cancer/Sarcoma-AdultSoftTissueCancer/DetailedGuide/sarcoma-adult-soft-tissue-cancer-soft-tissue-sarcoma ' target='_blank'>American Cancer Society</a> provides information on hemangioendothelioma in a fact sheet on soft-tissue sarcomas.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/pdq/treatment/child-soft-tissue-sarcoma/patient/' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/MESH:D006390' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":3694,"questionText":"What is a hemangioendothelioma?","answerText":"The term <strong>hemangioendothelioma</strong> describes several types of vascular <a href=\"http://www.cancer.gov/dictionary?cdrid=46264\" target=_blank>neosplasms</a> and includes both non-cancerous (benign) and cancerous (malignant) growths. The term has also been applied to those that show \"borderline\" behavior, intermediate between entirely benign <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001459.htm\" target=_blank>hemangiomas</a> and highly malignant <a href=\"http://www.curesarcoma.org/index.php/patient_resources/subtypes/angiosarcoma\" target=_blank>angiosarcomas</a>.[6103] Hemangioendotheliomas are caused by abnormal growth of blood vessel cells, although the exact underlying cause for the abnormal growth is unknown. They can also develop in an organ, such as the liver or lung. They usually grow slowly and can sometimes spread to other tissues in the body (metastasize).[2584][6103] Examples of types of hemangioendotheliomas include spindle cell hemangioma; papillary intralymphatic (Dabska tumor); retiform; kaposiform; epithelioid; pseudomyogenic (epithelioid sarcoma-like hemangioendothelioma); and composite.[6103] Treatment depends on the type of hemangioendothelioma present but typically includes surgical excision (removal).","dateModified":"2013-07-10T12:50:00"},"basicQuestions":[{"questionId":6957,"questionText":"How might hemangioendothelioma be treated?","answerText":"Treatment for hemangioendothelioma may depend on the type of hemangioendothelioma present in the affected individual and the risk of recurrence or metastases. In most reported cases, surgical excision (removal) of the mass has been the only treatment. For spindle cell hemangioma, simple excision is reportedly curative; however, new growths develop in adjacent skin and soft tissues in 60% of affected individuals. For individuals with papillary intralymphatic angioendothelioma (PILA), excision of the involved lymph nodes, as well as the mass, has been recommended. Surgical excision is reportedly also the usual treatment for individuals with retiform hemangioendothelioma (although local recurrence with this type is common), epithelioid hemangioendothelioma, and composite hemangioendothelioma (with the exception of 1 case treated with interferon).<br><br>Most individuals with pseudomyogenic hemangioendothelioma have been treated with simple excision, but a few individuals have also received post-surgical <a href=\"http://www.cancer.gov/cancertopics/factsheet/Therapy/radiation\" target=_blank>radiotherapy</a> (RT).<br><br>With regard to kaposiform hemangioendothelioma, some large lesions cannot be completely removed and may cause fatal complications due to the associated <a href=\"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&amp;Expert=2330\" target=_blank>Kasabach–Merritt syndrome</a>. In these cases, several medical therapies have been used, including <a href=\"http://www.dermnetnz.org/treatments/systemic-steroids.html\" target=_blank>systemic corticosteroids</a>; <a href=\"http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/interferons-alfa\" target=_blank>alfa interferon</a>; RT; embolization; and several other therapies, both alone and in various combinations.[6103]<br><br>A study by Scott et al published in 2012 in the American Journal of Clinical Oncology evaluated the effectiveness of RT as either an alternative or adjunct to surgery. The authors stated that the effectiveness of definitive RT in the treatment of hemangioendothelioma in their study implies that radiation may be an acceptable alternative when surgical resection will compromise function or cosmetic result. They concluded that with no local recurrences and minimal risk of toxicity, their long-term data suggest that RT offers a highly effective management option for this disease.[6104]","dateModified":"2013-07-10T11:41:00","resourceClassificationName":"Treatment","references":[{"referenceId":6103,"authors":"Requena L, Kutzner H","articleTitle":"Hemangioendothelioma","bookWebsiteJournalTitle":"Semin. Diagn. Pathol","date":"February 2013","volume":"30(1)","pages":"29-44"},{"referenceId":6104,"authors":"Michael T. Scott et al","articleTitle":"Radiation Therapy for Hemangioendothelioma: The University of Florida Experience","bookWebsiteJournalTitle":"American Journal of Clinical Oncology","date":"2012"}]},{"questionId":6958,"questionText":"What is the long-term outlook for individuals with hemangioendothelioma?","answerText":"The long-term outlook (prognosis) for individuals with hemangioendothelioma is not predictable and differs among affected individuals. The prognosis in each case depends on the type of hemangioendothelioma present, the risk of recurrence and whether the condition has metastasized (spread) to nearby tissues or other parts of the body. For example, although surgical removal of lesions of spindle cell hemangioendothelioma is considered curative, new masses develop in adjacent skin and soft tissues in 60% of the cases. However, among the approximately 200 cases of spindle cell hemangioma described in the literature, no patient has developed regional or distant metastases.[6103] Likewise, for individuals with retiform hemangioendothelioma, local recurrence is common but metastatic disease is rare.[6103] On the other hand, a follow-up study of 30 patients with cutaneous epithelioid hemangioendothelioma showed that 21% of the affected individuals developed systemic metastases, and 17% of these patients died as a consequence.[6103]<br><br>Survival rates in the literature for individuals with hemangioendothelioma generally range from 62% to 83% and local control rates (stopping cancer growth at the site of origin) range from 80% to 100%.[6104]","dateModified":"2013-07-10T12:47:00","resourceClassificationName":"Prognosis","references":[{"referenceId":6103,"authors":"Requena L, Kutzner H","articleTitle":"Hemangioendothelioma","bookWebsiteJournalTitle":"Semin. Diagn. Pathol","date":"February 2013","volume":"30(1)","pages":"29-44"},{"referenceId":6104,"authors":"Michael T. Scott et al","articleTitle":"Radiation Therapy for Hemangioendothelioma: The University of Florida Experience","bookWebsiteJournalTitle":"American Journal of Clinical Oncology","date":"2012"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":40199,"abbreviatedInquiry":"I have been told that surgery is really the only treatment for hemangioendothelioma; that chemo isn't used and that radiation only helps with the pain rather than shrink the tumors. Is this true? Also, what is the mortality rate or life expectancy for those with this type of cancer?","caseQuestions":[{"questionId":6957,"questionText":"How might hemangioendothelioma be treated?","answerText":"Treatment for hemangioendothelioma may depend on the type of hemangioendothelioma present in the affected individual and the risk of recurrence or metastases. In most reported cases, surgical excision (removal) of the mass has been the only treatment. For spindle cell hemangioma, simple excision is reportedly curative; however, new growths develop in adjacent skin and soft tissues in 60% of affected individuals. For individuals with papillary intralymphatic angioendothelioma (PILA), excision of the involved lymph nodes, as well as the mass, has been recommended. Surgical excision is reportedly also the usual treatment for individuals with retiform hemangioendothelioma (although local recurrence with this type is common), epithelioid hemangioendothelioma, and composite hemangioendothelioma (with the exception of 1 case treated with interferon).<br><br>Most individuals with pseudomyogenic hemangioendothelioma have been treated with simple excision, but a few individuals have also received post-surgical <a href=\"http://www.cancer.gov/cancertopics/factsheet/Therapy/radiation\" target=_blank>radiotherapy</a> (RT).<br><br>With regard to kaposiform hemangioendothelioma, some large lesions cannot be completely removed and may cause fatal complications due to the associated <a href=\"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&amp;Expert=2330\" target=_blank>Kasabach–Merritt syndrome</a>. In these cases, several medical therapies have been used, including <a href=\"http://www.dermnetnz.org/treatments/systemic-steroids.html\" target=_blank>systemic corticosteroids</a>; <a href=\"http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/interferons-alfa\" target=_blank>alfa interferon</a>; RT; embolization; and several other therapies, both alone and in various combinations.[6103]<br><br>A study by Scott et al published in 2012 in the American Journal of Clinical Oncology evaluated the effectiveness of RT as either an alternative or adjunct to surgery. The authors stated that the effectiveness of definitive RT in the treatment of hemangioendothelioma in their study implies that radiation may be an acceptable alternative when surgical resection will compromise function or cosmetic result. They concluded that with no local recurrences and minimal risk of toxicity, their long-term data suggest that RT offers a highly effective management option for this disease.[6104]","dateModified":"2013-07-10T11:41:00","resourceClassificationName":"Treatment","references":[{"referenceId":6103,"authors":"Requena L, Kutzner H","articleTitle":"Hemangioendothelioma","bookWebsiteJournalTitle":"Semin. Diagn. Pathol","date":"February 2013","volume":"30(1)","pages":"29-44"},{"referenceId":6104,"authors":"Michael T. Scott et al","articleTitle":"Radiation Therapy for Hemangioendothelioma: The University of Florida Experience","bookWebsiteJournalTitle":"American Journal of Clinical Oncology","date":"2012"}]},{"questionId":6958,"questionText":"What is the long-term outlook for individuals with hemangioendothelioma?","answerText":"The long-term outlook (prognosis) for individuals with hemangioendothelioma is not predictable and differs among affected individuals. The prognosis in each case depends on the type of hemangioendothelioma present, the risk of recurrence and whether the condition has metastasized (spread) to nearby tissues or other parts of the body. For example, although surgical removal of lesions of spindle cell hemangioendothelioma is considered curative, new masses develop in adjacent skin and soft tissues in 60% of the cases. However, among the approximately 200 cases of spindle cell hemangioma described in the literature, no patient has developed regional or distant metastases.[6103] Likewise, for individuals with retiform hemangioendothelioma, local recurrence is common but metastatic disease is rare.[6103] On the other hand, a follow-up study of 30 patients with cutaneous epithelioid hemangioendothelioma showed that 21% of the affected individuals developed systemic metastases, and 17% of these patients died as a consequence.[6103]<br><br>Survival rates in the literature for individuals with hemangioendothelioma generally range from 62% to 83% and local control rates (stopping cancer growth at the site of origin) range from 80% to 100%.[6104]","dateModified":"2013-07-10T12:47:00","resourceClassificationName":"Prognosis","references":[{"referenceId":6103,"authors":"Requena L, Kutzner H","articleTitle":"Hemangioendothelioma","bookWebsiteJournalTitle":"Semin. Diagn. Pathol","date":"February 2013","volume":"30(1)","pages":"29-44"},{"referenceId":6104,"authors":"Michael T. Scott et al","articleTitle":"Radiation Therapy for Hemangioendothelioma: The University of Florida Experience","bookWebsiteJournalTitle":"American Journal of Clinical Oncology","date":"2012"}]}]},{"caseId":27984,"abbreviatedInquiry":"What is a hemangioendothelioma?&nbsp; How common is it?","caseQuestions":[{"questionId":3694,"questionText":"What is a hemangioendothelioma?","answerText":"The term <strong>hemangioendothelioma</strong> describes several types of vascular <a href=\"http://www.cancer.gov/dictionary?cdrid=46264\" target=_blank>neosplasms</a> and includes both non-cancerous (benign) and cancerous (malignant) growths. The term has also been applied to those that show \"borderline\" behavior, intermediate between entirely benign <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001459.htm\" target=_blank>hemangiomas</a> and highly malignant <a href=\"http://www.curesarcoma.org/index.php/patient_resources/subtypes/angiosarcoma\" target=_blank>angiosarcomas</a>.[6103] Hemangioendotheliomas are caused by abnormal growth of blood vessel cells, although the exact underlying cause for the abnormal growth is unknown. They can also develop in an organ, such as the liver or lung. They usually grow slowly and can sometimes spread to other tissues in the body (metastasize).[2584][6103] Examples of types of hemangioendotheliomas include spindle cell hemangioma; papillary intralymphatic (Dabska tumor); retiform; kaposiform; epithelioid; pseudomyogenic (epithelioid sarcoma-like hemangioendothelioma); and composite.[6103] Treatment depends on the type of hemangioendothelioma present but typically includes surgical excision (removal).","dateModified":"2013-07-10T12:50:00","references":[{"referenceId":2584,"authors":"","articleTitle":"Sarcoma - Adult Soft Tissue Cancer","bookWebsiteJournalTitle":"American Cancer Society","date":"July 6, 2010","url":"http://www.cancer.org/Cancer/Sarcoma-AdultSoftTissueCancer/DetailedGuide/sarcoma-adult-soft-tissue-cancer-soft-tissue-sarcoma","dateAccessed":"2011-02-14T00:00:00"},{"referenceId":6103,"authors":"Requena L, Kutzner H","articleTitle":"Hemangioendothelioma","bookWebsiteJournalTitle":"Semin. Diagn. Pathol","date":"February 2013","volume":"30(1)","pages":"29-44"}]},{"questionId":3695,"questionText":"How common is hemangioendothelioma?","answerText":"Hemangioendotheliomas are very rare.&nbsp; The National Cancer Institute reported that only 21 people in the United States were diagnosed with hemangioendothelioma from 2003 to 2007. [2585]","dateModified":"2010-10-05T14:53:00","references":[{"referenceId":2585,"authors":"National Cancer Institute","articleTitle":"Soft Tissue Sarcomas, CSR 1975-2007","bookWebsiteJournalTitle":"SEER Cancer Statistics Review 1975-2007","date":"","url":"http://seer.cancer.gov/csr/1975_2007/results_merged/sect_35_soft_tissue_sarcomas.pdf","dateAccessed":"2010-09-29T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Hemangioendothelioma"}